Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IARS1 | P41252 | 4/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976875 | 1.00 | IARS1 (0.33) | IARS1F10 | |
| SCHEMBL14478983 | 1.00 | IARS1 (0.33) | IARS1F10 | |
| SCHEMBL6123884 | 0.87 | F10 (0.30) | IARS1F10 | |
| SCHEMBL13692694 | 0.87 | F10 (0.30) | F10 | |
| SCHEMBL12346246 | 0.86 | F10 (0.35) | F10 | |
| SCHEMBL730705 | 0.85 | F10 (0.35) | IARS1F10 | |
| SCHEMBL12892710 | 0.85 | F10 (0.35) | IARS1F10 | |
| SCHEMBL12895304 | 0.85 | F10 (0.35) | IARS1F10 | |
| SCHEMBL403268 | 0.81 | OGA (0.33) | IARS1 | |
| SCHEMBL14478994 | 0.80 | IARS1 (0.33) | IARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9877961-B2 | Anticoagulant reversal agents | PEROSPHERE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170056396-A1 | ANTICOAGULANT REVERSAL AGENTS | PINWHEEL THERAPEUTICS INC. | 2017-03-02 | — | — | US | disclosed |
| US-9522892-B2 | Anticoagulant reversal agents | PEROSPHERE INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160361501-A1 | MULTIPLE DOSE PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN AND/OR HEPARIN-LIKE COMPOUNDS AND DEVICES AND METHODS FOR DELIVERING THE SAME | VIRCHOW BIOTECH PVT. LTD. (IN) | 2016-12-15 | — | — | US | disclosed |
| US-9163047-B2 | Saccharide structures and methods of making and using such structures | MOMENTA PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140200339-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20130137702-A1 | ANTICOAGULANT REVERSAL AGENTS | PEROSPHERE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20110201801-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | MOMENTA PHARAMACEUTICALS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361501-A1 | MULTIPLE DOSE PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN AND/OR HEPARIN-LIKE COMPOUNDS AND DEVICES AND METHODS FOR DELIVERING THE SAME | HPSE, SERPINC1, PCSK6 | IARS1 3882/4885F10 29/4885 |
| US-20110201801-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | FUT6, FUT5, SI | IARS1 1650/4885F10 1627/4885 |
| US-20130137702-A1 | ANTICOAGULANT REVERSAL AGENTS | SERPINC1, F2, PROC | IARS1 4273/4885F10 12/4885 |
| US-20170056396-A1 | ANTICOAGULANT REVERSAL AGENTS | SERPINC1, F2, PROC | IARS1 4273/4885F10 12/4885 |
| US-20140200339-A1 | SACCHARIDE STRUCTURES AND METHODS OF MAKING AND USING SUCH STRUCTURES | FUT6, FUT5, SI | IARS1 1650/4885F10 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.